BACKGROUND: We recently established a novel assay for specific activity (SA) of cyclin-dependent kinases (CDKs) using small tumor samples (>/=8 mm(3)). The aim of this study was to investigate the prognostic significance of CDK1SA and CDK2SA in human breast cancer. METHODS: CDK1SA and CDK2SA were determined in 284 breast cancer patients and their prognostic significance was investigated. RESULTS: Tumors with high CDK1SA and high CDK2SA showed significantly poorer 5-year relapse-free survival than those with low CDK1SA and low CDK2SA, respectively (66.9% vs 84.2% for CDK1SA; 43.6% vs 83.6% for CDK2SA). Moreover, combined analysis of CDK1SA and CDK2SA enabled the classification of breast tumors into high-risk and low-risk groups, where tumors in the high-risk group were strongly associated with unfavorable prognosis (5-year relapse-free survival 69.4% for the high-risk group and 91.5% for the low-risk group). Multivariate analysis showed that the risk determined by combined analysis of CDK1SA and CDK2SA is a significant (hazard ratio 3.09, P < 0.001) prognostic indicator for relapse, especially in node-negative patients (hazard ratio 6.73, P < 0.001). CONCLUSION: Determination of CDK1SA and CDK2SA may be useful in the prediction of outcomes in breast cancer patients and has potential for use as a routine laboratory test.
BACKGROUND: We recently established a novel assay for specific activity (SA) of cyclin-dependent kinases (CDKs) using small tumor samples (>/=8 mm(3)). The aim of this study was to investigate the prognostic significance of CDK1SA and CDK2SA in humanbreast cancer. METHODS: CDK1SA and CDK2SA were determined in 284 breast cancerpatients and their prognostic significance was investigated. RESULTS:Tumors with high CDK1SA and high CDK2SA showed significantly poorer 5-year relapse-free survival than those with low CDK1SA and low CDK2SA, respectively (66.9% vs 84.2% for CDK1SA; 43.6% vs 83.6% for CDK2SA). Moreover, combined analysis of CDK1SA and CDK2SA enabled the classification of breast tumors into high-risk and low-risk groups, where tumors in the high-risk group were strongly associated with unfavorable prognosis (5-year relapse-free survival 69.4% for the high-risk group and 91.5% for the low-risk group). Multivariate analysis showed that the risk determined by combined analysis of CDK1SA and CDK2SA is a significant (hazard ratio 3.09, P < 0.001) prognostic indicator for relapse, especially in node-negative patients (hazard ratio 6.73, P < 0.001). CONCLUSION: Determination of CDK1SA and CDK2SA may be useful in the prediction of outcomes in breast cancerpatients and has potential for use as a routine laboratory test.
Authors: Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim Journal: Yonsei Med J Date: 2011-05 Impact factor: 2.759
Authors: Samina Alam; Brian S Bowser; Michael J Conway; Mohd Israr; Eric J Ryndock; Long Fu Xi; Craig Meyers Journal: J Virol Date: 2010-02-24 Impact factor: 5.103
Authors: Andreas Hedblom; Kristian B Laursen; Regina Miftakhova; Martuza Sarwar; Lola Anagnostaki; Anders Bredberg; Nigel P Mongan; Lorraine J Gudas; Jenny L Persson Journal: Cell Cycle Date: 2013-03-21 Impact factor: 4.534